Henry Schein (HSIC) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
19 Aug, 2026Executive summary
Achieved strong Q2 2026 results with total sales up 6.7% year-over-year to $3.5 billion, internal local currency sales growth of 4.6%, and early benefits from value creation initiatives.
Non-GAAP diluted EPS rose 15.5% to $1.27, GAAP diluted EPS was $0.82 (up 17.1% YoY), and adjusted EBITDA increased 12.7% to $288 million.
Raised FY2026 guidance for non-GAAP diluted EPS to $5.29–$5.39, sales growth to 4.5%–5.5%, and adjusted EBITDA growth to mid to high-single digits.
Focused on accelerating growth, simplifying operations, driving operational rigor, and deepening customer relationships to create sustainable shareholder value.
Advanced technology platforms, especially AI-enabled and cloud-based solutions, are driving higher customer profitability and engagement.
Financial highlights
Q2 2026 global sales reached $3.5 billion, up 6.7% year-over-year; internal local currency sales growth was 4.6%.
Non-GAAP operating income grew 10.5% to $250 million; non-GAAP EPS rose 15.5% to $1.27; adjusted EBITDA was $288 million (+12.7% YoY).
GAAP operating margin was 4.94% (+27 bps YoY); non-GAAP operating margin was 7.21% (+25 bps YoY); gross margin improved to 31.8%.
Q2 2026 GAAP net income was $94 million ($0.82/share); non-GAAP net income was $145 million ($1.27/share).
Operating cash flow for Q2 2026 was $242 million; share repurchases totaled $200 million in Q2, with $455 million authorized for future repurchases.
Outlook and guidance
FY2026 non-GAAP diluted EPS guidance raised to $5.29–$5.39, reflecting 6%-8% growth over 2025.
FY2026 total sales growth expected at 4.5%–5.5%; adjusted EBITDA growth projected mid to high-single digits.
Guidance excludes restructuring, amortization, and other non-recurring items; assumes stable FX rates and no further remeasurement gains or tariff refunds.
Earnings growth in Q4 expected to exceed Q3, driven by sales momentum and value creation benefits.
The restructuring plan is expected to continue through 2027, with further charges anticipated but not yet estimated.
Latest events from Henry Schein
- Global leader in dental and medical products with $13.2B sales and strong growth momentum.HSIC
Corporate presentation - Strategic initiatives and value creation projects drive stable growth and operational efficiency.HSIC
Baird Global Healthcare Conference 2025 - Transformation, innovation, and disciplined growth drive strong outlook and value creation.HSIC
Stifel Jaws & Paws Conference 2026 - Leadership changes, all proposals passed, and majority voting adopted for future governance.HSIC
AGM 2026 - Strong Q1 growth, margin expansion, and strategic focus position the company for 2026 targets.HSIC
Bank of America Global Healthcare Conference 2026 - Board urges support for director nominees and opposes majority vote proposal at annual meeting.HSIC
Proxy filing - Record Q3 2025 results, raised guidance, and $200M+ value creation initiatives announced.HSIC
Q3 2025 - Q2 2024 sales up 1.1% to $3.14B; net income and EPS declined, and guidance was reduced.HSIC
Q2 2024 - Q4 2024 non-GAAP EPS rose 80% on 5.8% sales growth; 2025 outlook targets steady gains.HSIC
Q4 2024